Stereocomplexes for the delivery of anti-cancer agents
US-2024350644-A1 · Oct 24, 2024 · US
Methods and compositions for treating or preventing narcotic withdrawal symptoms
US9226918B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9226918-B2 |
| Application number | US-63162809-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2009 |
| Priority date | Dec 4, 2008 |
| Publication date | Jan 5, 2016 |
| Grant date | Jan 5, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention provides methods and pharmaceutical compositions for preventing or treating physical dependence and/or withdrawal associated with narcotic use, in particular by modulating a 5-HT3 receptor. Using a computational genetic approach in mice, a gene conserved between mice and humans was identified as candidate as a modulator of physical dependence to morphine. Administration of compounds that modulate 5-HT3 receptors was found to control withdrawal from morphine in mice and humans.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating physical dependence and/or withdrawal symptoms associated with narcotic use, comprising administering to a human subject in need thereof a pharmaceutical composition consisting essentially of (1) a narcotic compound selected from the group consisting of morphine, hydrocodone, oxycodone, hydromorphone, and oxymorphone, buprenorphine and a combination of buprenorphine and naloxone, wherein said composition is administered at a dose of between 2 and 25 mg/70 kg of subject; and (2) a 5-HT3 receptor antagonist in a dose effective to reduce physical dependence and/or withdrawal symptoms associated with said narcotic use, wherein the narcotic compound and the 5-HT3 receptor antagonist are co-administered. 2. The method of claim 1 further comprising the step of administering to said human subject an antiemetic antihistamine.
Assignees
Inventors
Classifications
Morphinan derivatives, e.g. morphine, codeine · CPC title
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title
- A61K31/4178Primary
not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin · CPC title
Opioid-abuse · CPC title
containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9226918B2 cover?
- This invention provides methods and pharmaceutical compositions for preventing or treating physical dependence and/or withdrawal associated with narcotic use, in particular by modulating a 5-HT3 receptor. Using a computational genetic approach in mice, a gene conserved between mice and humans was identified as candidate as a modulator of physical dependence to morphine. Administration of compou…
- Who is the assignee on this patent?
- Peltz Gary, Clark David, Chu Lawrence, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4178. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).